Published in Cytopathology on January 01, 1993
Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review. Postgrad Med J (2003) 0.77
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med (1988) 4.06
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol (2001) 3.94
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet (1998) 3.06
Diagnostic value of an immunoassay to detect anti Campylobacter pylori antibodies in non-ulcer dyspepsia. Lancet (1989) 3.03
Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol (2000) 2.97
A large-scale prospective cohort study on diet and cancer in The Netherlands. J Clin Epidemiol (1990) 2.96
Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol (1994) 2.92
Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol (2008) 2.73
Glutamine and the preservation of gut integrity. Lancet (1993) 2.72
Ductal carcinoma in-situ of the breast; second EORTC consensus meeting. Eur J Cancer (1992) 2.67
[The treatment of ductal carcinoma in situ (DCIS) of the breast]. Ned Tijdschr Geneeskd (2003) 2.67
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol (2001) 2.51
Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer (2003) 2.40
[Dutch Institute for Healthcare Improvement guideline, "Treatment of breast cancer"]. Ned Tijdschr Geneeskd (2002) 2.39
The preferential interaction of cholesterol with different classes of phospholipids. Biochim Biophys Acta (1977) 2.32
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
Prognostic significance of radial margins of clearance in rectal cancer. Br J Surg (1996) 2.15
A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem (1999) 2.15
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol (1997) 2.15
E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer (1997) 2.02
Differential features of gastric cancer patients, either Helicobacter pylori positive or Helicobacter pylori negative. Ital J Gastroenterol Hepatol (1999) 2.02
Helicobacter pylori and gastric carcinoma. Histopathology (1990) 1.98
The impact of tumor size and histology on local control after breast-conserving therapy. Radiother Oncol (1988) 1.83
Proliferating cell nuclear antigen (PCNA): a new marker to study human colonic cell proliferation. Gut (1994) 1.82
Modern life' in the epidemiology of inflammatory bowel disease: a case-control study with special emphasis on nutritional factors. Eur J Gastroenterol Hepatol (1998) 1.80
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
Antibody phage display technology and its applications. Immunotechnology (1998) 1.79
A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer (1988) 1.72
Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg (2000) 1.71
Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction. J Mol Cell Cardiol (1993) 1.66
Somatostatin-receptor scintigraphy in primary breast cancer. Lancet (1994) 1.63
EB/RP gene family encodes tubulin binding proteins. Int J Cancer (1999) 1.63
Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST) Eur J Cancer (1999) 1.55
Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res (1992) 1.53
Classification of gastric carcinoma using the Goseki system provides prognostic information additional to TNM staging. Cancer (1999) 1.50
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer (2003) 1.50
Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer (2000) 1.50
Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer (1999) 1.46
Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat (2008) 1.45
The prevalence of Helicobacter pylori serum antibodies in children with recurrent abdominal pain. Eur J Pediatr (1992) 1.44
Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. Eur J Surg Oncol (2001) 1.44
[Diagnostics in clinically occult, radiologically suspect breast lesions more often surgery than needle diagnostics with image monitoring]. Ned Tijdschr Geneeskd (2001) 1.43
Evaluation of a cytological scoring system for predicting histological grade and disease-free survival in primary breast cancer. Cytopathology (1994) 1.42
[Identification of the sentinel node in patients with breast carcinoma]. Ned Tijdschr Geneeskd (1996) 1.42
[Detailed pathological examination of the sentinel lymph nodes in order to detect micrometastases: no clinical relevance in patients with breast cancer]. Ned Tijdschr Geneeskd (2004) 1.40
Tenascin and fibronectin expression in healing human myocardial scars. J Pathol (1996) 1.40
[Tumor markers in screening, diagnosis and treatment of patients with breast carcinoma]. Ned Tijdschr Geneeskd (1993) 1.38
Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol (2011) 1.36
Lymphoepithelioma-like carcinoma of the breast: lack of evidence of Epstein-Barr virus infection. Histopathology (2001) 1.32
Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer (2003) 1.31
The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Ann Surg (1992) 1.31
A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett (1999) 1.30
Efforts to improve interobserver agreement in histopathological grading. J Clin Epidemiol (1995) 1.30
Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. Histopathology (2005) 1.27
Type IV collagen immunoreactivity in colorectal cancer. Prognostic value of basement membrane deposition. Cancer (1988) 1.26
Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch (1999) 1.24
Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum (1988) 1.24
Acinic cell carcinoma of the breast: an immunohistochemical and ultrastructural study. Virchows Arch (2000) 1.24
No-touch isolation technique in colon cancer: a controlled prospective trial. Br J Surg (1988) 1.23
Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer (2001) 1.22
MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer (1998) 1.21
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology (2007) 1.21
Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res (1994) 1.21
No common denominator for breast cancer lymph node metastasis. Br J Cancer (2005) 1.20
Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol (2004) 1.19
Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union--an inter-laboratory study. Virchows Arch (2004) 1.19
Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol (2001) 1.19
Diagnostic accuracy for different strategies of image-guided breast intervention in cases of nonpalpable breast lesions. Br J Cancer (2004) 1.18
Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma (1983) 1.18
Interobserver variation in histopathological grading of cervical dysplasia. J Clin Epidemiol (1990) 1.18
Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer (2007) 1.17
Rapid staining of Campylobacter pyloridis. Histopathology (1987) 1.17
Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer (1999) 1.17
Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer (2001) 1.16
The prevalence of anti-Helicobacter (Campylobacter) pylori antibodies in patients and healthy blood donors. J Med Microbiol (1990) 1.14
Factors influencing noncompliance and contamination in a randomized trial of "Western" (r1) versus "Japanese" (r2) type surgery in gastric cancer. Cancer (1994) 1.13
Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol (1997) 1.13
In-situ breast cancer: the EORTC consensus meeting. Lancet (1989) 1.13
A prospective cohort study on dietary fat and the risk of postmenopausal breast cancer. Cancer Res (1993) 1.13
Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library. Eur J Biochem (1999) 1.11
Presence of Helicobacter pylori in patients with non-ulcer dyspepsia revealing normal antral histological characteristics. Digestion (1990) 1.11
Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer (2005) 1.10
Toker cells are probably precursors of Paget cell carcinoma: a morphological and ultrastructural description. Virchows Arch (2002) 1.09
Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol (2009) 1.09
Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol (1999) 1.08
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol (2006) 1.08
Inflammatory bowel disease: is there any relation between smoking status and disease presentation? European Collaborative IBD Study Group. Inflamm Bowel Dis (1998) 1.08
Alveolar soft part sarcoma. a report of 15 cases. Eur J Cancer (2002) 1.08
Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes. Cancer (2000) 1.07